Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Should You Water Grass While It’s Sunny? - Expert Advice

Watering the lawn is a fundamental part of keeping your garden green and healthy. But with so many conflicting opinions floating around, it can be confusing to know exactly when to water your grass. A common question many homeowners ask is: should you water your grass while it's sunny?   [A sprinkler spraying water on grass Description automatically generated]   Here, gardening expert Fiona Jenkins at MyJobQuote.co.uk  delves into the world of lawn care and explores the pros and cons of watering during sunny spells, along with expert advice to

DOF GROUP ASA - Extraordinary General Meeting

Austevoll, 26 July 2024: Reference is made to the stock exchange announcement made by DOF Group ASA (the "Company", OSE ticker code "DOFG") on 2 July 2024 regarding an agreement to acquire Maersk Supply Service A/S (the "Transaction"), and on 5 July 2024 regarding an extraordinary general meeting to be held on 26 July 2024 (the "EGM"). The EGM was held today as a digital meeting with online participation. All proposals on the agenda were adopted, cf. the notice of the EGM that was published on 5 July 2024. The EGM elected two new board members: Erik Bergöö as the vice chairperson of the

Eisai will seek re-examination of CHMP opinion för lecanemab

Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will request re-examination of the Committee for Medicinal Products for Human Use (CHMP’s) negative opinion posted today on the Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer’s disease in the EU.“We are surprised and very disappointed by the CHMP’s opinion posted today. Foremost  the negative opinion adopted by the CHMP is sad for all patients, caregivers and healthcare professionals in the EU who will now have to wait longer for a

CHMP has adopted a negative opinion on lecanemab for the EU

Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion on BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai’s Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer’s disease. BioArctic is currently consulting Eisai regarding forthcoming actions. A further update will be communicated later todayLecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, and Israel and is being marketed in

Ellos Group announces that it has received an acceleration notice in respect of its outstanding bonds and contemplates a standstill agreement with major bondholders

Press release, Borås, 26 July 2024 On 14 July 2024, Ellos Group AB (publ) (“Ellos Group” or the “Company”) announced that the Company had initiated a constructive dialogue with certain holders under the Company’s outstanding SEK 1,500,000,000 senior secured bonds due 25 July 2024 (the “Senior Bonds”) and SEK 250,000,000 super senior secured bonds due 9 February 2025 (jointly, the “Existing Bonds”) to find a long-term refinancing solution for the Existing Bonds and to strengthen Ellos Group’s capital structure. In connection with the Company’s inability to repay the Senior Bonds at

$5.5 Million Raised in the United States to Preserve Finnish Cultural Heritage

Finnish cultural heritage in the United States faced an existential threat, but donors stepped in. Now, over $5.5 million has been raised to preserve the unique Finnish-America history.Finlandia Foundation National (FFN), a non-profit organization dedicated to preserving Finnish cultural heritage in the US, has announced the results of the "Saving Finland in America" campaign. Over 900 individual donors, families, organizations, and nonprofit foundations across Finnish-America have donated a record-breaking $5.5 million to ensure the preservation of the unique Finnish-American cultural

Cell Impact and F.C.C. take their collaboration to the next level

The collaboration between Cell Impact and Japanese F.C.C. continues to deepen. Recently, the two companies undertook a joint effort to position Cell Impact Forming™ in China.In China, Cell Impact and F.C.C. visited several customers and prospects to display the benefits of Cell Impact Forming and the opportunities for large-scale production in Asia that the collaboration with F.C.C. offers. Some of the companies visited was Nowogen, Anchor, and Horizon Fuel Cell Technologies, of which Nowogen is one of Cell Impact’s early customers. “This visit is a great example of how the deepened

Post Stabilisation Notice

DZ Bank AG: Post-Stabilisation Notice Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. DZ BANK AG (contact: Ralph Ockert; telephone: +49 69 7447 7051) herebygives notice that no stabilisation (within the meaning of Article 3.2 (d) of the Market Abuse Regulation (EU Regulation 596/2014) was undertaken by the Stabilising Managers named below in relation to the offer of the following securities. The security to be stabilised: Issuer:                           European Union (EU)

Post -Stabilisation Notice

DZ Bank AG: Post-Stabilisation Notice Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. DZ BANK AG (contact: Ralph Ockert; telephone: +49 69 7447 7051) herebygives notice that no stabilisation (within the meaning of Article 3.2 (d) of the Market Abuse Regulation (EU Regulation 596/2014) was undertaken by the Stabilising Managers named below in relation to the offer of the following securities. The security to be stabilised: Issuer:                           European Union (EU)

Correction of previous press release

The press release that was published earlier today on 26 July 2024 at 08:00 CET has been updated with the right cash flow figures for Vehicles and Services as it previously showed the cash flow figures for Scania Group. The rest of the press release is unchanged.Strong financial performance in the second quarter, with significant growth in sales and earnings. • Scania Group net sales grew by 9 percent to SEK 55.4 billion (51.0) • Adjusted operating income reached SEK 8.0 billion (7.0) and adjusted operating margin was 14.5 percent (13.6) • Vehicle deliveries increased by 8 percent

CasinoRank Network Unveils Major Menu Redesign Across Its Websites

Stockholm, Sweden, 26 July 2024 – CasinoRank Network is thrilled to announce a major redesign of the menu across its websites. This significant update aims to enhance technological progression, SEO optimization, and automation improvements, providing users with a more seamless and intuitive browsing experience.After months of meticulous planning and development, the CasinoRank team has launched a revamped menu system that caters to the unique content of each specific website within the network. For example, OnlineCasinoRank now features dedicated sections for table game reviews, while

Dampskibsselskabet NORDEN A/S – final weekly report on share buy-back

ANNOUNCEMENT NO. 169 – 26 JULY 2024   On 25 April 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 26 April 2024 up to and including no later than 1 August 2024. For details, please see announcement no. 96 of 25 April 2024.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 21 million (approximately DKK 145 million).

Arctic Bioscience – Mandatory notification of trade

Nils Erik Bjørkedal, a person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has bought 10.000 shares in Arctic Bioscience at an average price of NOK 10,42 per share. Following the transaction, Nils Erik Bjørkedal holds 10.000 shares in Arctic Bioscience.Nils Erik Bjørkedal is closely associated with the Quality Manager in Arctic Bioscience, Jannicke Bjørkedal. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR)

CS MEDICA Leverages Strategic Partnerships for CANNASEN® Brand Launch in APAC and MENA

Launching 36,000 Units to Test Market Fit and Accelerate Market Penetration at a value of €419,000CS MEDICA announces an advancement in its expansion strategy with the upcoming launch of CANNASEN® in the Asia-Pacific (APAC) and Middle East/North Africa (MENA) regions. This launch utilizes strong partnerships and a Minimum Viable Product (MVP) approach to establish the CANNASEN® brand. CS MEDICA will distribute 36,000 units of CANNASEN® to APAC and MENA at a value of €419,000 starting August 2024. This initiative aims to gather consumer insights to perfect product alignment and readiness

Sleep Cycle interim report April – June 2024: Laying the foundation for continued sustainable and profitable growth

Gothenburg, Sweden – 26 July, 2024The second quarter in summary (April-June 2024) · Net sales totaled tSEK 65,442 (57,952) and increased by 12.9% (11.0%). Currency-adjusted net sales growth amounted to 10.5% (1.1%). · Operating profit amounted to tSEK 20,964 (12,732), with an operating margin of 32.0% (22.0%). · Adjusted operating profit totaled tSEK 20,964 (17,265) and adjusted operating margin was 32.0% (29.8%). · The total number of paying subscribers at end of period was 898k (877k). · ARPU in the quarter amounted to SEK 282 (263). Currency adjusted ARPU was SEK 277.

SAS files monthly operating reports with U.S. court and announces certain financial information for the Group

SAS AB (“SAS” or the “Company”) and each of its subsidiaries that are subject to the voluntary chapter 11 process in the U.S. will shortly file monthly operating reports, containing certain financial information for the period of November 1, 2023 to June 30, 2024 with the U.S. Bankruptcy Court for the Southern District of New York (the “Court”). All SAS companies that are subject to the voluntary chapter 11 process are each required to file operating reports with the Court on a monthly basis. The financial information contained in the monthly operating reports includes items such as cash

Terrafame's operating result for January–June 2024 improved year-on-year

The financial information presented about Terrafame Ltd in this media release consists of unaudited IFRS figures. The figures in brackets refer to the corresponding period in the previous year unless otherwise stated. April−June 2024 in brief: · Net sales were EUR 116.0 (91.4) million, representing an increase of 21.2% year-on-year. · Net sales from the battery chemicals business decreased to EUR 29.4 (32.1) million, or 25.3% (35.1) of the company’s total net sales. Net sales were negatively affected by lower production and delivery volumes as well as a decrease in the market

Hexagon Interim Report 1 January - 30 June 2024

Second quarter 2024 • 0 per cent organic revenue growth (using fixed exchange rates and a comparable group structure)• Net sales decreased by -1 per cent to 1,353.4 MEUR (1,366.0)• Net sales including the reduction of acquired deferred revenue amounted to 1,353.4 MEUR (1,365.0)• Adjusted gross margin of 67.3 per cent (65.6)• Adjusted operating earnings (EBIT1) increased by 1 per cent to 399.5 MEUR (394.1)• Adjusted operating margin amounted to 29.5 per cent (28.9)• Earnings per share, excluding adjustments, amounted to 10.8 Euro cent (10.8)• Earnings per share, including

Transaction in Own Shares

    26 July 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |25/07/2024|+--------------------------------------------------------------

2024 AGM Statement

FIRSTGROUP PLC 2024 AGM STATEMENT   FirstGroup plc (‘FirstGroup’ or ‘the Group’) will be holding its Annual General Meeting (‘AGM’) at 14:30 today.   Trading Ahead of the AGM, the Group notes that its overall trading performance for the financial year-to-date has been in line with the expectations we outlined at our full year results on 11 June 2024.   London Cable Car Operation On 28 June 2024, the Group successfully took over the operation of the IFS Cloud London Cable Car on behalf of Transport for London (‘TfL’). The contract has an initial core five-year term

Half-year report, Q2 2024

January–June 2024 compared with January–June 2023  · Net sales increased to SEK 9,849m (9,395). The sales increase was mainly as a result of higher delivery volumes due to a gradual ramp up of production at mills where strategic capital expenditures have recently been made. · EBITDA amounted to SEK 3,484m (3,755). Lower selling prices were offset by higher delivery volumes, positive exchange rate effects and effective cost control. · EBITDA margin was 35.4% (40.0). · Operating profit declined to SEK 2,438m (2,825). · Operating cash flow amounted to SEK 1,203m (1,851). ·

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo.  The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness.The TRANSFORM trial is a double-blind, randomized, placebo-controlled Phase 2b study investigating the effect of setanaxib 800 mg AM + 400 mg PM, (“1200 mg arm”) and 800 mg BID (“1600 mg

There are no items matching the current filter
There are no more items matching the current filter
Back to top